Previous studies have shown that inflammatory parameters can be used to assess the prognosis of cancer patients, such as serum C-reactive protein (CRP), neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte rate (PLR), and neutrophil to lymphocyte ratio (NLR), which are two types of hematological indicators commonly used in clinical research and practice and have a good predictive value for evaluating the postoperative survival of NSCLC [4–8]. This evidence concerns the gene CRP and cancer.